Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B

For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.